Cost–Effectiveness of Hepatitis C Virus Antiviral Treatment for Injection Drug User Populations

Abstract

Despite the possibility of reinfection, the model suggests providing antiviral treatment to IDUs is the most cost-effective policy option in chronic prevalence scenarios less than 60%. Further research on how HCV treatment for injectors can be scaled up and its impact on prevalence is warranted.